Speaker Profile
M.D., Director, Institute for Aging Research; President, Academy for Health & Lifespan Research., Albert Einstein College of Medicine
Biography
Dr. Nir Barzilai is a preeminent leader in geroscience, demonstrating in his studies that aging has its own biology that drives age-related diseases, a process that can be targeted. At Albert Einstein College of Medicine, he is a professor in the departments of Medicine and Genetics, the director of the Institute for Aging Research, and the director of the Einstein-National Institutes of Health (NIH) Nathan Shock Center of Excellence in the Basic Biology of Aging, and the author of 350 papers. He made seminal discoveries in extending the health and lifespan of animals and discovering pathways for exceptional longevity in humans. He is leading an international effort to approve drugs targeting aging. Targeting Aging with Metformin (TAME) is a specific study conceived by Dr. Barzilai to prove that a single drug can combat multiple diseases associated with aging and get FDA approval for targeting aging. Dr. Barzilai is a co-founder and the President of A HLS. He is also on the board of directors of the American Federation for Aging Research, where he co-leads its biomarker effort (FAST), TAME, and Super Agers initiative. He is an Executive of the Longevity Biotech Association (LBA) and serves on the Healthy Longevity Medicine Society council. He authored Age Later: Health Span, Life Span, and the New Science of Longevity.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Michael Goldman, SFSU
PMWC Award Ceremony
• David Sinclair, Harvard
• Steve Horvath, Altos Labs
• Nir Barzilai, Albert Einstein College of Medicine
AI-Driven Biomarkers to Quantify Aging
• Chair: Alex Zhavoronkov, Insilico Medicine
• Mahdi Moqri, Harvard
• Steve Horvath, Altos Labs
Epigenetic Aging Signatures in Large Human Cohorts
• Varun Dwaraka, TruDiagnostic
AI Systems for Personalized Longevity: How Biomarkers Translate into Actionable Interventions
• Chair: Nathan Price, Buck Institute
• Sherry Zhang, Buck Institute
• Ranjan Sinha, Digbi Health
Epigenetic Rejuvenation & Delivery for Clinical Translation
• Chair: Ryan (Yuancheng) Lu, Whitehead Institute/MIT
• David Sinclair, Harvard
Clinical Trial Design & Functional Endpoints for Healthspan
• Nir Barzilai, Albert Einstein College of Medicine
• Martin Jensen, Gordian Biotechnology
From Genome to an AI-Drive Longevity Platform/b>
• Wei-Wu He, Human Longevity
• Hussain Ahamed, Ultrahuman
Precision Aging & Longevity Focused on Limited Lifespan Evidence, Vanishing Blue Zones, and Payer ROI
• S. Jay Olshansky, University of Illinois
• Michael Gurven, UC Santa Barbara
